Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of utidelone injection plus bevacizumab in non-small cell lung cancer with brain metastases
CTR20244543Phase 2Active
- Sponsor
- 成都华昊中天药业有限公司
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone, bevacizumab in non-small cell lung cancer (NSCLC), sponsored by 成都华昊中天药业有限公司. Started Feb 2025; status: active.
02
Drugs
utidelonebevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244543.